In-Person Access Only | 8.0 CE/CME Credits

All programs remain free. Registrations will require a credit card as a cancellation hold. A fee of $99 will only be incurred in the event of a no-show or cancellation within 5 days without written confirmation to the Total Health Program Team.

Total Health’s 2026 ASCO Direct™ Genitourinary Cancer Conference is an officially licensed ASCO Direct™ meeting. This Post-ASCO Genitourinary Cancers Symposium Review highlights key abstracts from top-rated presentations, providing attendees with direct access to the latest research and strategies in GU oncology education. The accredited meeting will be hosted as an in person meeting only available exclusively to registered participants.

Conference Agenda

Saturday, March 14, 2026

8:00 AM
Coffee and Exhibits

8:30 AM
Program Chair Welcome
Pedro Barata | University Hospitals

8:40 AM
My Top Abstracts from ASCO GU 2026
Michael Serzan | Harvard

9:10 AM
Evolving Treatment Paradigms in GU Cancer Care

9:40 AM
Breakfast and Exhibits

9:55 AM
Non CME Breakfast

10:40 AM
Updates in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Ravi Madan

11:10 AM
Treatment Sequencing in Metastatic Hormone-Sensitive Prostate Cancer

11:40 AM
PSMA-Targeted Therapies & Imaging

12:10 PM
Lunch and Exhibits

12:25 PM
Non CME Lunch

1:10 PM
Housekeeping & Survey

1:20 PM
Frontline Immunotherapy in Metastatic Urothelial Carcinoma

1:50 PM
Bladder Preservation Strategies

2:20 PM
Targeted Therapy for FGFR-Altered Tumors

2:50 PM
Adjourn


Sunday, March 15, 2026

8:00 AM
Coffee and Exhibits

8:30 AM
Program Chair Welcome
Bradley McGregor | Dana-Farber Cancer Institute

8:40 AM
Kidney Cancer Highlights from ASCO GU 2026

9:10 AM
First-Line Therapy in Metastatic RCC

9:40 AM
Breakfast and Exhibits

9:55 AM
Non CME Breakfast

10:40 AM
Adjuvant Therapy in Localized RCC

11:10 AM
Biomarker-Driven Strategies for RCC

11:40 AM
Lunch and Exhibits

11:55 AM
Non CME Lunch

12:40 PM
Genomic Profiling in GU Malignancies

1:10 PM
Toxicity Management in Immunotherapy & Targeted Therapy

1:40 PM
Case-Based Multidisciplinary Tumor Board

2:10 PM
Adjourn

Agenda Subject To Change. All times are EST.

• Learning Objectives

  • Review and analyze the latest therapeutic advances for the treatment and management of GU cancers

  • Apply new data and therapeutic advances into guideline-driven treatment strategies to improve the care of patients with prostate, bladder, kidney, and other genitourinary cancers

  • Identify subpopulations of patients with GU cancers most likely to benefit from specific treatment plans based on prognostic or predictive markers

  • Evaluate the role of circulating tumor DNA (ctDNA) and minimal residual disease (MRD) in GU cancers

• Accreditation Information 8.0 CE/CME Credits

  In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Total Health. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

  Nurses (ANCC) Credit Designation

  Amedco LLC designates this activity for a maximum of 8.0 ANCC contact hours.

  Physicians (ACCME) Credit Designation

  Amedco LLC designates this live activity for a maximum of 8.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  Pharmacists and Pharmacy Technicians (ACPE) Credit Designation

  Amedco LLC designates this activity for a maximum of 8.0 knowledge-based CPE contact hours.

  NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.

• What to Expect | In-Person Learners

  • Free registration for all healthcare providers

  • Expert sessions that present the most clinically relevant data, research, and clinical strategies

  • Real-time discussion and debate

  • Networking with peers, colleagues, and medical professionals

  • Access to the latest industry information and resources